ALX Oncology Holdings Inc. (NASDAQ:ALXO) shares, rose in value on Friday, 08/05/22, with the stock price up by 5.62% to the previous day’s close as strong demand from buyers drove the stock to $11.47.
Actively observing the price movement in the last trading, the stock closed the session at $10.86, falling within a range of $10.05 and $11.685. The value of beta (5-year monthly) was 2.15. Referring to stock’s 52-week performance, its high was $81.19, and the low was $5.82. On the whole, ALXO has fluctuated by 17.52% over the past month.
With the market capitalization of ALX Oncology Holdings Inc. currently standing at about $577.06 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 16, 2022 – Mar 21, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.63, which is expected to increase to -$0.58 for fiscal year -$2.66 and then to about -$3.15 by fiscal year 2023. Data indicates that the EPS growth is expected to be -28.50% in 2023, while the next year’s EPS growth is forecast to be -18.40%.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that ALXO’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ALXO currently trading nearly 7.54% and 29.56% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 60.26, while the 7-day volatility ratio is showing 9.05% which for the 30-day chart, stands at 8.47%. Furthermore, ALX Oncology Holdings Inc. (ALXO)’s average true range (ATR) is 0.84.
A comparison of ALX Oncology Holdings Inc. (ALXO) with its peers suggests the former has fared considerably weaker in the market. ALXO showed an intraday change of 5.62% in last session, and over the past year, it shrunk by -82.81%%. In comparison, Johnson & Johnson (JNJ) has moved lower at -0.40% on the day and was down -1.49% over the past 12 months. On the other hand, the price of Eli Lilly and Company (LLY) has fallen -1.46% on the day. The stock, however, is off 14.05% from where it was a year ago. Additionally, there is a loss of -1.18% for Pfizer Inc. (PFE) in last trading while the stock has seen an overall depriciation of 9.34%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.16%. Meanwhile, the Dow Jones Industrial Improved by 0.23%.
Data on historical trading for ALX Oncology Holdings Inc. (NASDAQ:ALXO) indicates that the trading volumes over the past 10 days have averaged 0.22 million and over the past 3 months, they’ve averaged 458.59K. According to company’s latest data on outstanding shares, there are 40.62 million shares outstanding.
Nearly 1.20% of ALX Oncology Holdings Inc.’s shares belong to company insiders and institutional investors own 88.50% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.91 million shares as on Jul 14, 2022, resulting in a short ratio of 6.63. According to the data, the short interest in ALX Oncology Holdings Inc. (ALXO) stood at 9.61% of shares outstanding as of Jul 14, 2022; the number of short shares registered in Jun 14, 2022 reached 4.62 million. The stock has fallen by -46.63% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ALXO stock heading into the next quarter.